GLAXOSMITHKLINE PLC Form 6-K April 12, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending April 2016

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

_

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons

In accordance with DTR 3.1.4R(1)(a) GlaxoSmithKline plc ('GSK') was advised on 12 April 2016 that the following Directors and Persons Discharging Managerial Responsibilities ('PDMR') acquired GSK Ordinary Shares ('Shares') on 11 April 2016, at a price of 1472.57 pence per Ordinary Share, through GSK's ShareReward Plan (the 'Plan'):

Director/PDMR		sNumber of Shares under althe matching element of atthe Plan (GSK contribution)
Sir Andrew Witty	9	9
Mr R G Connor	9	9
Mr S Dingemans	9	9
Mr N Hirons	9	9
Mr S A Hussain	9	9
Mr D S Redfern	9	9
Ms C Thomas	9	9
Mr P C Thomson	9	9
Dr P J T Vallance	8	8
Ms E Walmsley	9	9
Mrs V A Whyte	9	9

V A Whyte Company Secretary

12 April 2016

SIGNATURES

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to	be
signed on its behalf by the undersigned, thereunto duly authorised.	

GlaxoSmithKline plc (Registrant)

Date: April 12, 2016

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc